Sandra Marshall
Family · North Wilkesboro, NCNPI 1992438998
Payments from drug & device makers
Across 187 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$533
- Novo Nordisk$465
- AstraZeneca$357
- Collegium Pharmaceutical, Inc.$215
- Indivior Inc.$211
- Otsuka America Pharmaceutical, Inc.$150
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,146100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $533 |
| Novo Nordisk | 35 | $465 |
| AstraZeneca | 17 | $357 |
| Collegium Pharmaceutical, Inc. | 11 | $215 |
| Indivior Inc. | 11 | $211 |
| Otsuka America Pharmaceutical, Inc. | 7 | $150 |
| Lilly USA, LLC | 7 | $143 |
| GSK | 6 | $111 |
| Forte Bio-pharma LLC | 5 | $106 |
| Virtus Pharmaceuticals LLC | 5 | $102 |
| Bayer | 6 | $99 |
| Shield Therapeutics Inc | 6 | $99 |
| Exact Sciences | 5 | $85 |
| Pfizer | 5 | $82 |
| Gilead | 3 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Scilex Pharmaceuticals Inc. | 2 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Dexcom, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| Mylan Specialty L.p. | 1 | $21 |
| Amgen | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Viatris Specialty LLC | 1 | $18 |
How this compares
$3,146 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 334 | $205,044 |
| MounjaroTirzepatide | 144 | $157,662 |
| OzempicSemaglutide | 162 | $155,597 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 853 | $121,741 |
| RybelsusSemaglutide | 89 | $91,747 |
| Xtampza ErOxycodone Myristate | 78 | $33,933 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $27,639 |
| BelbucaBuprenorphine Hcl | 32 | $26,369 |
| LinzessLinaclotide | 31 | $25,200 |
| EliquisApixaban | 29 | $23,620 |
| VraylarCariprazine Hcl | 12 | $18,317 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 484 | $14,289 |
| Oxycodone Hcl | 787 | $14,102 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,339 |
| DapagliflozinDapagliflozin Propanediol | 26 | $12,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $465 | $247,344251 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $357 | $238,971403 claims |
| Lilly USA, LLCMounjaro | $143 | $157,662144 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $215 | $60,303110 claims |
| AbbVieLinzess, Vraylar | $533 | $43,51743 claims |
| PfizerEliquis | $82 | $23,62029 claims |
| GSKTrelegy Ellipta | $111 | $13,33917 claims |
| Boehringer IngelheimCombivent Respimat, Stiolto Respimat | $23 | $12,83025 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $50 | $10,66713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.
Other family in North Wilkesboro
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.